<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03230097</url>
  </required_header>
  <id_info>
    <org_study_id>1289.32</org_study_id>
    <secondary_id>2016-004973-42</secondary_id>
    <secondary_id>1289-0032</secondary_id>
    <nct_id>NCT03230097</nct_id>
  </id_info>
  <brief_title>This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year</brief_title>
  <official_title>A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to
      placebo given for 52 weeks to subjects with attenuated psychosis syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Anticipated">May 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first episode of psychosis</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in everyday functional capacity as measured by Schizophrenia Cognition Rating Scale (SCoRS) total score after 24 and 52 weeks of treatment</measure>
    <time_frame>Baseline, Week 24 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the BAC App composite T score after 52 weeks of treatment</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS) positive items score, negative items score, and total score after 52 weeks of treatment</measure>
    <time_frame>Baseline and Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Psychotic Disorders</condition>
  <arm_group>
    <arm_group_label>BI 409306</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>twice daily</description>
    <arm_group_label>BI 409306</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Meet diagnostic criteria for attenuated psychosis syndrome as defined in DSM-5 and
             determined by SIPS administered at screening and diagnosis confirmed by NeuroCog
             Trials after review of video-taped SIPS interview.

          -  North American Prodromal Longitudinal Study (NAPLS) risk calculator score ≥ 0.20 at
             screening.

          -  Age ≥16 and ≤ 30 years at the time of consent/assent.

          -  Male or female patients willing to use highly effective methods of contraception.

               -  Female patients of childbearing potential must be ready and able to use highly
                  effective methods of birth control per ICH M3 (R2) that result in a low failure
                  rate of less than 1% per year when used consistently and correctly. Patients must
                  agree to use birth control throughout the trial and for at least 28 days after
                  treatment has ended. Acceptable methods of birth control include combined
                  estrogen-progestin oral, intravaginal or transdermal contraceptives,
                  progestogen-only oral, injectable or implantable contraceptives, intrauterine
                  devices (IUDs), intrauterine hormone releasing systems (IUSs), bilateral tubal
                  occlusion, vasectomized sexual partner, and complete sexual abstinence (if
                  acceptable by local health authorities) is allowed when this is in line with the
                  preferred and usual lifestyle of the patient. Periodic abstinence (e.g.,
                  calendar, ovulation, symptom-thermal, post-ovulation methods) and withdrawal are
                  not acceptable methods of contraception.

               -  Male patients who are able to father a child must be ready and able to be
                  abstinent or use adequate contraception for the duration of study participation
                  and for at least 28 days after treatment has ended.

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation prior to any study-related procedures OR signed and dated
             informed consent provided by the patient's parent(s) (or legal guardian) and assent by
             the patient prior to any study-related procedures in accordance with GCP and local
             legislation. If the patient has a legal representative, then this legal representative
             must give written informed consent as well.

        Exclusion criteria

          -  Present or past diagnosis of schizophrenia, schizophreniform, schizoaffective
             disorder, bipolar disorder I, major depressive disorder with psychotic features,
             delusional disorder, brief psychotic disorder, other specified schizophrenia spectrum
             and other psychotic disorder (except attenuated psychosis syndrome), and unspecified
             schizophrenia spectrum and other psychotic disorder, according to DSM-5.

          -  Patients taking antipsychotic medication for less than 8 weeks prior to informed
             consent.

          -  Patients who begin taking an antipsychotic between Visit 1 and Visit 2.

          -  Patients who have discontinued an antipsychotic medication less than two weeks prior
             to randomization.

          -  Patients taking Clozapine.

          -  Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,
             aborted attempt, or preparatory acts or behavior).

          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale
             (CSSRS) in the past 3 months (i.e. active suicidal thought with intent but without
             specific plan, or active suicidal thought with plan and intent).

          -  In the judgment of the investigator, any clinically significant finding from the
             physical examination or laboratory value deviating from normal or any evidence of a
             clinically significant concomitant disease or any other clinical condition that would
             jeopardize a patient's safety while participating in the clinical trial.

          -  Known diseases of the central nervous system (including but not limited to any kind of
             seizures or stroke).

          -  History of significant head injury (&gt;5 minutes without consciousness).

          -  A serious developmental disorder that in the judgement of the investigator would
             inhibit the patient's ability to comply with all study procedures, or mental
             retardation (documented IQ &lt;70), or acute attenuated symptoms exclusively related to
             intoxication from a psychotropic substance.

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin or
             in situ carcinoma of uterine cervix.

          -  Planned elective surgery requiring general anesthesia, or hospitalization for more
             than 1 day during the study period.

          -  Significant history of drug or alcohol dependence or abuse (Substance Use Disorder as
             defined in DSM-5) within the last six months prior to informed consent/assent.

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial.

          -  Patients taking strong or moderate CYP1A2 inhibitors who are also a CYP2C19 Poor
             Metabolizer (PM). Patients taking medication known to be a strong or moderate
             inhibitor of CYP1A2 must be prospectively genotyped to ensure they are not poor
             metabolizers of CYP2C19. (A list of CYP1A2 and CYP2C19 inhibitors can be found in the
             ISF.).

          -  Patients taking strong or moderate CYP1A2 inhibitors who are also taking concomitant
             strong or moderate CYP2C19 inhibitors. (A list of CYP1A2 and CYP2C19 inhibitors can be
             found in the ISF.)

          -  Patients with a history of moderate to severe hepatic impairment (Child-Pugh B / C).

          -  Patients with a history of moderate to severe renal impairment (Stage 3 - 5).

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

          -  In the judgment of the investigator, inability of the patient to comply with the
             clinical trial procedures.

          -  Currently enrolled in another investigational device or drug study, or less than 30
             days since ending another investigational device or drug study(s), or receiving other
             investigational treatment(s).

          -  Previous participation in any BI 409306 study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bussel</last_name>
      <phone>+001 (424) 227-8127</phone>
      <email>marina.bussel@prosciencerg.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PRIME Clinic</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Woods</last_name>
      <phone>+001 (203) 974-7038</phone>
      <email>scott.woods@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute of Miami</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moraima Trujillo</last_name>
      <phone>+001 (305) 246-0001</phone>
      <email>mtrujillo@ariomfl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Cuffe</last_name>
      <phone>+001 (904) 244-3990</phone>
      <email>steven.cuffe@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lifestream Behavioral Center</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Valente</last_name>
      <phone>+001 (352) 315-7806</phone>
      <email>tjvalente@lsbc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adly Thebaud</last_name>
      <phone>+001 (386) 775-7627</phone>
      <email>athebaud@mrgcf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph McEvoy</last_name>
      <phone>+001 (919) 819-9295</phone>
      <email>JMcEvoy@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michigan Clinical Research Institute PC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajaprabhakaran Rajarethinam</last_name>
      <phone>+001 (734) 834-8954</phone>
      <email>rpmmc@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Taylor</last_name>
      <phone>+001 (734) 936-4955</phone>
      <email>sftaylor@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherry Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Achtyes</last_name>
      <phone>+001 (616) 965-8200</phone>
      <email>ericachtyes@cherryhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precise Research Centers</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kwentus</last_name>
      <phone>+001 (601) 420-5810</phone>
      <email>jkwentus@precise-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac</last_name>
      <phone>+001 (702) 527-7401</phone>
      <email>kunovacmd@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Kantrowitz</last_name>
      <phone>+001 (646) 774-6738</phone>
      <email>Kantrow@NYSpi.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson</last_name>
      <phone>+001 (585) 241-9670</phone>
      <email>sda@flclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Keefe</last_name>
      <phone>+001 (919) 684-4306</phone>
      <email>Richard.keefe@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caleb Adler</last_name>
      <phone>+001 (513) 558-3362</phone>
      <email>ADLERCB@UCMAIL.UC.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Medical Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alireza Parsoei</last_name>
      <phone>+001 (458) 205-6444</phone>
      <email>aparsoei@peacehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasas Tanguturi</last_name>
      <phone>+001 (615) 936-3288</phone>
      <email>yasas.c.tanguturi@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown</last_name>
      <phone>+001 (512) 323-2622</phone>
      <email>david.brown@communityclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajinder Shiwach</last_name>
      <phone>+001 (972) 331-8748</phone>
      <email>rshiwach@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hills Clinical Research</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ann Knesevich</last_name>
      <phone>+001 (972) 717-6262</phone>
      <email>maknesevich@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psychiatric and Behavioral Solutions, LLC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Reimherr</last_name>
      <phone>+001 (801) 467-1200</phone>
      <email>Fred.reimherr@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vishal Madaan</last_name>
      <phone>+001 (434) 243-3678</phone>
      <email>vm8d@virginia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Raedler</last_name>
      <phone>403 210-6899</phone>
      <email>Thomas.Raedler@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chatham-Kent Clinical Trials Research Centre</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7L 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranjith Chandrasena</last_name>
      <phone>519-397-3791</phone>
      <email>rchandrasena@ckctrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holywell Hospital</name>
      <address>
        <city>Antrim</city>
        <zip>BT41 2RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciaran Mulholland</last_name>
      <phone>+44 28 909 72167</phone>
      <email>c.c.mulholland@qub.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Barberry National Centre for Mental Health</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavan Mallikarjun</last_name>
      <phone>+44 (0)121 301 2367</phone>
      <email>p.mallikarjun@bham.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagore Penades</last_name>
      <phone>0141 849 2250</phone>
      <email>nagore.penades@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>WC2R 2LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip McGuire</last_name>
      <phone>020 784 80355</phone>
      <email>philip.mcguire@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

